1.- Gleeson EM, Dichiara MG, Salicio A, Quinn LM, Drakeford C, Russell SE, Walsh PT, Orbe J, Hermida J, Smith OP, O'Donnell JS, Montes R, Preston RJS. Activated protein C β-glycoform mediates superior cellular resistance to inflammation and ischemic injury. Blood 2015;126:915-9.
IF (2013): 9.775; Lugar: 2/68 Hematology; 1er decil

2.- Orbe J, Rodríguez JA, Sánchez-Arias JA, Salicio A, Belzunce M, Ugarte A, Chang HC, Rabal O, Oyarzabal J, Páramo JA. Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-m ethylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem. 2015;58(7):2941-57.
IF (2013): 5.480; Lugar: 3/58 Chemistry, Medicinal; 1er decil

3. Orbe J, Sánchez-Arias JA, Rabal O, Rodríguez JA, Salicio A, Ugarte A, Belzunce M, Xu M, Wu W, Tan H, Ma H, Páramo JA, Oyarzabal J. Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead. J Med Chem. 2015;58(5):2465-88.
IF (2013): 5.480; Lugar: 3/58 Chemistry, Medicinal; 1er decil

4. Gomez-Rodriguez V, Orbe J, Martinez-Aguilar E, Rodriguez JA, Fernandez-Alonso L, Serneels J, Bobadilla M, Perez-Ruiz A, Collantes M, Mazzone M, Paramo JA, Roncal C. Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia. FASEB J. 2015;29(3):960-72.
IF (2013): 5.480; Lugar: 7/85 Biology; 1er decil

5. Martinez-Aguilar E, Gomez-Rodriguez V, Orbe J, Rodriguez JA, Fernández-Alonso L, Roncal C, Páramo JA. Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease.J Vasc Surg. 2015 Feb;61(2):428-35.
IF (2013): 2.980; Lugar: 30/204 Surgery; 1er cuartil

6. Tamayo I, Velasco SE, Puy C, Esmon CT, Dichiara MG, Montes R, Hermida J. Group V secretory phospholipase A2 impairs endothelial protein C receptor-dependent protein C activation and accelerates thrombosis in vivo. J Thromb Haemost. 2014;12(11):1921-7.
IF (2013): 5.550; Lugar: 7/68 Hematology; 1er cuartil

7.- Toni M, Hermida J, Goñi MJ, Fernández P, Parks WC, Toledo E, Montes R, Díez N. Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients. Diabetologia. 2013;56(12):2743-52.
IF (2013): 6.880; Lugar: 11/124 Endocrinology & Metabolism; 1er decil

8. Rodríguez JA, Sobrino T, Orbe J, Purroy A, Martínez-Vila E, Castillo J, Páramo JA. proMetalloproteinase-10 is associated with brain damage and clinical outcome in acute ischemic stroke. J Thromb Haemost. 2013;11(8):1464-73.
IF (2013): 5.550; Lugar: 7/68 Hematology; 1er cuartil

9. Hernández C, Orbe J, Roncal C, Alvarez-Hernandez M, Martinez de Lizarrondo S, Alves MT, García Mata J, Páramo JA. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients. Thromb Haemost. 2013;110(3):598-608.
IF (2013): 5.760; Lugar: 6/68 Hematology; 1er decil

10. López-Sagaseta J, Puy C, Tamayo I, Allende M, Cerveró J, Velasco SE, Esmon CT, Montes R, Hermida J. sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove. Blood. 2012;119(12):2914-21.
IF (2012): 9.060; Lugar: 3/67 Hematology; 1er decil

11. Martínez de Lizarrondo S, Roncal C, Calvayrac O, Rodríguez C, Varo N, Purroy A, Lorente L, Rodríguez JA, Doeuvre L, Hervás-Stubbs S, Angles-Cano E, Páramo JA, Martínez-González J, Orbe J. Synergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2012;32(6):1477-87.
IF (2012): 6.638; Lugar: 4/68 Peripheral Vascular Disease; 1er decil

12. Orbe J, Barrenetxe J, Rodriguez JA, Vivien D, Orset C, Parks WC, Birkland TP, Serrano R, Purroy A, Martinez de Lizarrondo S, Angles-Cano E, Páramo JA. Matrix metalloproteinase-10 effectively reduces infarct size in experimental stroke by enhancing fibrinolysis via a thrombin-activatable fibrinolysis inhibitor-mediated mechanism. Circulation. 2011;124(25):2909-19.
IF (2011): 14.739; Lugar: 1/117 Cardiac and Cardiovascular Systems; 1er decil

13. Cerveró J, Montes R, España F, Esmon CT, Hermida J. Limited ability to activate protein C confers left atrial endocardium a thrombogenic phenotype: a role in cardioembolic stroke?.Stroke. 2011;42(9):2622-4.
IF (2011): 5.729; Lugar: 14/192 Clinical Neurology; 1er decil

14. Coll B, Rodríguez JA, Craver L, Orbe J, Martínez-Alonso M, Ortiz A, Díez J, Beloqui O, Borras M, Valdivielso JM, Fernández E, Páramo JA. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010;78(12):1275-80.
IF (2010): 6.105; Lugar: 3/69 Urology and Nephrology; 1er decil

15. Centelles MN, Puy C, López-Sagaseta J, Fukudome K, Montes R, Hermida J. Blocking endothelial protein C receptor (EPCR) accelerates thrombus development in vivo. Thromb Haemost. 2010;103(6):1239-44.
IF (2010): 4.701; Lugar: 13/66 Hematology; 1er cuartil


"Hemos identificado dos nuevos mecanismos, uno implicado en la fibrosis del miocardio que facilita la insuficiencia cardíaca, y otro en el daño cerebral secundario al ictus isquémico aterotrombótico", Dr. Javier Díez, director del programa.


Nerea Cano
Avda. Pío XII, 55
31008 Pamplona

(+34) 948 194 700 Ext. 3044